Seeking Alpha

Alkermes (ALKS) says subjects enrolled in a Phase 1 study of ALKS 3831 demonstrated...

Alkermes (ALKS) says subjects enrolled in a Phase 1 study of ALKS 3831 demonstrated "significantly less weight gain" than those taking Zyprexa alone. ALKS hopes to attenuate the weight gains typically associated with the schizophrenia treatment olanzaprine. "Diminishing this side effect could open [the drug's] therapeutic benefits to a wider range of patients," ALKS' Chief Medical Officer Elliot Ehrich notes. (PR)
Comments (1)
  • bil4Bill
    , contributor
    Comments (21) | Send Message
     
    a great company and one of their great pipeline products.
    28 May 2013, 11:41 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs